Pulmonary hypertension and right ventricular failure in critical care medicine

被引：1
作者：
F.J. Meyer
H.A. Katus
M.M. Borst
机构：
[1] Abt. Innere Medizin III (Schwerpunkt Kardiologie, Angiologie, und Pneumologie), Universität klinikum Heidelberg, 69120 Heidelberg
来源：
Der Pneumologe | 2008年 / 5卷 / 3期
关键词：
Intensive care medicine; Pulmonary embolism; Pulmonary hypertension; Right ventricular failure; Therapy;
D O I：
10.1007/s10405-008-0232-x
中图分类号：
学科分类号：
摘要：
The management of pulmonary hypertension and right ventricular failure in hemodynamically unstable patients is one of the most challenging situations in critical care medicine. Inadequate therapy, e.g. aggressive fluid resuscitation or invasive ventilation, may even harm patients with pulmonary hypertension. Identifying the underlying etiology therefore remains the primary focus for initiating successful management of patients with decompensated pulmonary hypertension and right ventricular failure. Pulmonary embolism requires immediate restoration of pulmonary vascular patency. The body of evidence from studies is scarce and favors dobutamine, NO inhalation, and intravenous prostacyclin. However, the use of other vasoactive substances, inotropes, and supportive measures has been successful in individual patients; it should be guided by the expected effects on the pulmonary vasculature or right ventricle, and should be adapted to the patient's concomitant diseases. © Springer Medizin Verlag 2008.
引用
收藏
页码：163 / 174
页数：11
相关论文
共 51 条
[1]  
Hoeper M.M., Galie N., Murali S., Et al., Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension, Am J Respir Crit Care Med, 165, pp. 341-344, (2002)
[2]  
Simmeneau G., Galie N., Rubin L.J., Et al., Clinical classification of pulmonary hypertension, J Am Coll Cardiol, 43, (2004)
[3]  
Humbert M., Morrell N.W., Archer S.L., Et al., Cellular and molecular pathobiology of pulmonary arterial hypertension, J Am Coll Cardiol, 43, pp. 1425-1436, (2004)
[4]  
Holzmann A., MankTelow C., Weimann J., Et al., Inhibition of lung phosphodiesterase improves responsiveness to inhaled nitric oxide in isolated-perfused lungs from rats challenged with endotoxin, Intensive Care Med, 27, pp. 251-257, (2001)
[5]  
Nath J., Foster E., Heidenreich P.A., Et al., Impact of tricuspid regurgitation on long-term survival, J Am Coll Cardiol, 43, pp. 405-409, (2004)
[6]  
Chin K.M., Kim N.H., Rubin L.J., The right ventricle in pulmonary hypertension, Coron Artery Dis, 16, pp. 13-18, (2005)
[7]  
The right ventricle: Anatomy, physiology, and clinical importance, Probl Cardiol, 16, pp. 653-720, (1991)
[8]  
Olschewski H., Hoeper M.M., Borst M.M., Et al., Diagnostik und Therapie der chronischen pulmonalen Hypertonie, Pneumologie, 60, pp. 749-771, (2006)
[9]  
Leuchte H.H., El Nounou M., Tuerpe J.C., Et al., N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension, Chest, 131, pp. 402-409, (2007)
[10]  
Klinger J.R., Thaker S., Houtches J., Et al., Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension, Chest, 129, pp. 417-425, (2006)
123456